Preclinical characterization of GLS4, an inhibitor of Hepatitis B virus core particle assembly

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5344-5354

  Wu, Guoyi ^a   Liu, Bo ^b   Zhang, Yingjun ^c   Li, Jing ^c   Arzumanyan, Alla ^a   Clayton, Marcia M ^a   Schinazi, Raymond F ^d   Wang, Zhaohe ^c   Goldmann, Siegfried ^c   Ren, Qingyun ^c   Zhang, Faxhou ^c   Feitelson, Mark A ^a  

^a Temple University   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c Guangdong East Sunshine Pharmaceutical Co Ltd   (China)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BAY 41 4109; GLS 4; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; VIREMIA; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; LAMIVUDINE; MALE; MICE; MICE, NUDE; MICROBIAL SENSITIVITY TESTS; PRIMARY CELL CULTURE; PYRIDINES; PYRIMIDINES; THIAZOLES; VIRAL CORE PROTEINS; VIREMIA; VIRION; VIRUS REPLICATION;

EID: 84885924778     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01091-13     Document Type: Article

References (48)

1. Tiollais P, Pourcel C, Dejean A. 1985. The hepatitis B virus. Nature 317:489-495.
2. Beasley RP, Hwang LY. 1984. Epidemiology of hepatocellular carcinoma, p 209-224. In Vyas GN, Dienstag JL, Hoofnagle JH (ed), Viral hepatitis and liver disease. Grune and Stratton, Inc., New York, NY.
3. Szmuness W. 1978. Hepatocellular carcinoma and HBV: evidence for a causal association. Prog. Med. Virol. 24:40-69.
4. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and HBV. A prospective study of 22,707 men in Taiwan. Lancet ii:1129-1132.
5. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, for the REVEAL-HBV Study Group. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73.
6. Geier A, Gartung C, Dietrich CG. 2002. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 347:1721-1722.
7. Bock CT, Schranz P, Schröder CH, Zentgraf H. 1994. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 8:215-229.
8. Mason WS, Aldrich C, Summers J, Taylor JM. 1982. Asymmetric replication of duck hepatitis B virus DNA in liver cells: free minus-strand DNA. Proc. Natl. Acad. Sci. U. S. A. 79:3997-4001.
9. Summers J, Mason WS. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
10. Bartenschlager R, Junker-Niepmann M, Schaller H. 1990. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J. Virol. 64:5324-5332.
11. Weigand K, Knaust A, Schaller H. 2010. Assembly and export determine the intracellular distribution of hepatitis B virus core protein subunits. J. Gen. Virol. 91:59-67.
12. Das A, Maini MK. 2010. Innate and adaptive immune responses in hepatitis B virus infection. Dig. Dis. 28:126-132.
13. Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P. 2007. Interferon therapy for chronic hepatitis B. Clin. Liver Dis. 11:839-849.
14. Min AD, Dienstag JL. 2007. Oral antivirals for chronic hepatitis B. Clin. Liver Dis. 11:851-868.
15. Jacquard AC, Nassal N, Pichoud C, Ren S, Schultz U, Guerret S, Chevallier M, Werle B, Peyrol S, Jamard C, Rimsky LT, Trepo C, Zoulim F. 2004. Effect of a combination of clevudine and emtricitabine and adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infections. Antimicrob. Agents Chemother. 48:2683-2692.
16. Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, Mondou E, Snow A, Sorbel J, Rousseau F, for the FTCB-204 Study Group. 2006. Randomized, double-blinded study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob. Agents Chemother. 50:1642-1648.
17. Feitelson MA, Clayton MM, Sun B, Schinazi RF. 2007. Development of a novel mouse model to evaluate drug candidates against hepatitis B virus. Antivir. Chem. Chemother. 18:213-223.
18. Jayaweera D, Dilanchian P. 2012. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data. Expert Opin. Pharmacother 13:2601-2612.
19. Deres K, Schröder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Krämer T, Niewöhner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rübsamen-Waigmann H. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299:893-896.
20. Pan XB, Han JC, Wei L, Peng DD, Gao Y. 2008. Subcellular distribution and translocation of hepatitis B virus core protein in HepG2.2.15 cells. Zhonghua Gan Zang Bing Za Zhi 16:29-32. (In Chinese.)
21. Wu GY, Zheng XJ, Yin CC, Jiang D, Zhu L, Liu Y, Wei L, Wang Y, Chen HS. 2008. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J. Chemother. 20:458-467.
22. Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F. 2011. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res. 92:271-276.
23. Stray SJ, Zlotnick A. 2006. BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly. J. Mol. Recognit. 19:542-548.
24. Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E, Deres K, Goldmann S, Niewoehner U, Stoltefuss J, Haebich D, Ruebsamen-Waigmann H, Wohlfeil S. 2002. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 54:69-78.
25. Brezillon N, Brunelle MN, Massinet H, Giang E, Lamant C, DaSilva L, Berissi S, Belghiti J, Hannoun L, Puerstinger G, Wimmer E, Neyts J, Hantz O, Soussan P, Morosan S, Kremsdorf D. 2011. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One 6:e25096.
26. Wang XY, Wei ZM, Wu GY, Wang JH, Zhang YJ, Li J, Zhang HH, Xie XW, Wang X, Wang ZH, Wei L, Wang Y, Chen HS. 2012. In vitro inhibition ofHBVreplication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir. Ther. 17: 793-803.
27. Shi C, Wu CQ, Cao AM, Sheng HZ, Yan XZ, Liao MY. 2007. NMRspectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats. Toxicol. Lett. 173:161-167.
28. Hacker HJ, Deres K, Mildenberger M, Schroder CH. 2003. Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion. Biochem. Pharmacol. 66: 2273-2279.
29. Siegfried G, Jing L, Liu YS. November 2012. Bromo-phenyl substituted thiazolyl dihydropyrimidines. US patent application publication no. US 2012/0282221 A1.
30. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
31. Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. 2009. Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/ nucleotide analogues. Antivir. Chem. Chemother. 19:165-176.
32. Larkin J, Clayton MM, Sun B, Perchonock CE, Morgan JL, Siracusa LD, Michaels F, Feitelson MA. 1999. Hepatitis B virus transgenic SCID mouse model of chronic liver disease. Nat. Med. 5:907-912.
33. Zlotnick A, Ceres P, Singh S, Johnson JM. 2002. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J. Virol. 76: 4848-4854.
34. Santos NC, Castanho MA. 1996. Teaching light scattering spectroscopy: the dimension and shape of tobacco mosaic virus. Biophys. J. 71:1641-1650.
35. Chen H, Lü JH, Liang WQ, Huang YH, Zhang WJ, Zhang DB. 2004. Purification of the recombinant hepatitis B virus core antigen (rHBcAg) produced in the yeast Saccharomyces cerevisiae and comparative observation of its particles by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Micron 35:311-318.
36. Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. 2005. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl. Acad. Sci. U. S. A. 102:8138-8143.
37. Lian Z, Liu J, Li L, Li X, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, Feitelson MA. 2006. Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with up-regulation of -catenin. Hepatology 43:415-424.
38. Summers J, Smith PM, Horwich AL. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
39. Sells MA, Zelent AZ, Shvartsman M, Acs G. 1988. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62:2836-2844.
40. Li L, Chirapu SR, Finn MG, Zlotnick A. 2013. Phase diagrams map the properties of antiviral agents directed against hepatitis B virus core assembly. Antimicrob. Agents Chemother. 57:1505-1508.
41. Parkin DM, Bray F, Ferlay J, PIsani P. 2001. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94:153-156.
42. Broelsch CE, Frilling A, Malago M. 2004. Hepatoma -resection or transplantation. Surg. Clin. North Am. 84:495-511.
43. de Wilt JHW, van Etten B. 2004. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg. Clin. North Am. 84:627-642.
44. Elias D, de Baere T, Sideris L, Ducreux M. 2004. Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surg. Clin. N. Am. 84:607-626.
45. Nicholl MB, Bilchik AJ. 2008. Thermal ablation of hepatic malignancy: useful but still not optimal. Eur. J. Surg. Oncol. 34:318-323.
46. Strumberg D. 2005. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 41:773-784.
47. Gollob JA, Wilhelm S, Carter C, Kelley SL. 2006. Role of raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33:392-406.
48. Flaherty KT. 2007. Sorafenib: delivering a targeted drug to the right targets. Expert Rev. Anticancer Ther. 7:617-626.